A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients

Pharmacogenetics and Genomics

Volumn 23, Issue 8, 2013, Pages 445-448

  Tavira, Beatriz ^a   Coto, Eliecer ^a,b,c   Diaz Corte, Carmen ^a,b   Alvarez, Victoria ^a   López Larrea, Carlos ^a,b,c   Ortega, Francisco ^a,c  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

^c Unidad de Hemodialisis 'Los Lauros'   (Spain)

Author keywords

CYP3A4; CYP3A5; cytochrome P450; pharmacokinetics; polymorphism; tacrolimus

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ENZYME VARIANT; TACROLIMUS;

ADULT; ALLELE; ARTICLE; COHORT ANALYSIS; DOSE CALCULATION; EVENING DOSAGE; EXON; GENE EXPRESSION; GENE SEQUENCE; GENETIC CODE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MORNING DOSAGE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

EID: 84880917962     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283636856     Document Type: Article

References (13)

1. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007; 2:374-384
2. Dai Y, Hebert MF, Isoherranen N, Marsh C, Shen DD, Thummel KE. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34:836-847
3. Haufroid V,Wallemacq P, VanKerckhove V, Elens L, De Meyer M, Eddour DC, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 2006; 6:2706-2713
4. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87:721-726
5. Tavira B, Coto E, Diaz-Corte C, Ortega F, Arias M, Torres A, et al. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin Chem Lab Med 2011; 49:825-833
6. Wang D, Guo Y,Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011; 11:274-286
7. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57:1574-1583
8. Kamdem LK, Streit F, Zanger UM, Brockmö ller J, Oellerich M, Armstrong VW,Wojnowski L. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005; 51:1374-1381
9. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 50-upstream regulatory region. Biochem Biophys Res Commun 1999; 259:201-205
10. Amirimani B, Ning B, Deitz AC,Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 2003; 42:299-305
11. Kuypers D. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging 2009; 26: 715-737
12. Hesselink DA, Ngyuen H, Wabbijn M, Gregoor PJ, Steyerberg EW, van Riemsdijk IC, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol 2003; 56:327-330
13. Van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003; 16:721-725.